NVP-BEZ235 Inhibits Thyroid Cancer Growth by P53- Dependent/independent P21 Upregulation

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2020 Feb 7

PMID 32025215

Citations 8

Authors

Banjun Ruan

Wei Liu

Pu Chen

Rongrong Cui

Yu Li

Meiju Ji

Peng Hou

Qi Yang

Affiliations

Soon will be listed here.

Abstract

NVP-BEZ235 is a novel dual PI3K/mTOR inhibitor, currently in phase 1/2 clinical trials, exhibiting clinical efficiency in treatment of numerous malignancies including thyroid cancer. Cancer cells harboring mutant p53 was widely reported to be blunt to pharmaceutical therapies. However, whether this genotype dependent effect also presents in thyroid cancer when treated with NVP-BEZ235 remains unknown. Therefore, in this study, the tumor suppressing effects of NVP-BEZ235 in thyroid cancer cell lines and xenograft mouse model harboring different p53 status were examined. The antitumor effects were confirmed in p53 mutant thyroid cancer cells, though less prominent than p53 wild type cells. And for the p53 mutant cells, p53-independent upregulation of p21 plays a critical role in their response to NVP-BEZ235. Moreover, GSK3β/β-catenin signaling inhibition was implicated in the p21-mediated G/G cell cycle arrest in both p53 wild type and mutant thyroid cancer cells treated with NVP-BEZ235.

Citing Articles

Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer.

Liu X, Xu W, Li L, Zhang Z, Lu M, Xia X Int J Med Sci. 2024; 21(10):1814-1823.

PMID: 39113885 PMC: 11302559. DOI: 10.7150/ijms.84320.

Protein-Bound Uremic Toxins in Senescence and Kidney Fibrosis.

Yang Y, Mihajlovic M, Masereeuw R Biomedicines. 2023; 11(9).

PMID: 37760849 PMC: 10525416. DOI: 10.3390/biomedicines11092408.

Design of new drugs for medullary thyroid carcinoma.

Li Y, Luo Z, Wang X, Zhang S, Hei H, Qin J Front Oncol. 2022; 12:993725.

PMID: 36544713 PMC: 9760674. DOI: 10.3389/fonc.2022.993725.

The impact of senescence on muscle wasting in chronic kidney disease.

Huang Y, Wang B, Hassounah F, Price S, Klein J, Mohamed T J Cachexia Sarcopenia Muscle. 2022; 14(1):126-141.

PMID: 36351875 PMC: 9891952. DOI: 10.1002/jcsm.13112.

A Human Conditionally Immortalized Proximal Tubule Epithelial Cell Line as a Novel Model for Studying Senescence and Response to Senolytics.

Yang Y, Mihajlovic M, Valentijn F, Nguyen T, Goldschmeding R, Masereeuw R Front Pharmacol. 2022; 13:791612.

PMID: 35422705 PMC: 9002109. DOI: 10.3389/fphar.2022.791612.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M . Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer. J Urol. 2013; 191(1):227-34. DOI: 10.1016/j.juro.2013.07.101. View

Saji M, Ringel M . The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2009; 321(1):20-8. PMC: 2849843. DOI: 10.1016/j.mce.2009.10.016. View

Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K . Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem. 2002; 277(24):21843-50. DOI: 10.1074/jbc.M109745200. View

Cheok C, Verma C, Baselga J, Lane D . Translating p53 into the clinic. Nat Rev Clin Oncol. 2010; 8(1):25-37. DOI: 10.1038/nrclinonc.2010.174. View

Sipos J, Mazzaferri E . Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010; 22(6):395-404. DOI: 10.1016/j.clon.2010.05.004. View

Stewart Z, Leach S, Pietenpol J . p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol Cell Biol. 1998; 19(1):205-15. PMC: 83879. DOI: 10.1128/MCB.19.1.205. View

Blandino G, Di Agostino S . New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37(1):30. PMC: 5815234. DOI: 10.1186/s13046-018-0705-7. View

Karimian A, Ahmadi Y, Yousefi B . Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst). 2016; 42:63-71. DOI: 10.1016/j.dnarep.2016.04.008. View

10.

Chapuis N, Tamburini J, Green A, Vignon C, Bardet V, Neyret A . Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010; 16(22):5424-35. DOI: 10.1158/1078-0432.CCR-10-1102. View

11.

Perri F, Pisconti S, Della Vittoria Scarpati G . P53 mutations and cancer: a tight linkage. Ann Transl Med. 2017; 4(24):522. PMC: 5233470. DOI: 10.21037/atm.2016.12.40. View

12.

Santo L, Siu K, Raje N . Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Semin Oncol. 2015; 42(6):788-800. DOI: 10.1053/j.seminoncol.2015.09.024. View

13.

Xing M . Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013; 13(3):184-99. PMC: 3791171. DOI: 10.1038/nrc3431. View

14.

Kamei J, Toyofuku T, Hori M . Negative regulation of p21 by beta-catenin/TCF signaling: a novel mechanism by which cell adhesion molecules regulate cell proliferation. Biochem Biophys Res Commun. 2003; 312(2):380-7. DOI: 10.1016/j.bbrc.2003.10.129. View

15.

Manzella L, Stella S, Pennisi M, Tirro E, Massimino M, Romano C . New Insights in Thyroid Cancer and p53 Family Proteins. Int J Mol Sci. 2017; 18(6). PMC: 5486146. DOI: 10.3390/ijms18061325. View

16.

Nikiforova M, Nikiforov Y . Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2007; 8(1):83-95. DOI: 10.1586/14737159.8.1.83. View

17.

Santiskulvong C, Konecny G, Fekete M, Chen K, Karam A, Mulholland D . Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res. 2011; 17(8):2373-84. PMC: 3078990. DOI: 10.1158/1078-0432.CCR-10-2289. View

18.

van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A . The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002; 111(2):241-50. DOI: 10.1016/s0092-8674(02)01014-0. View

19.

Lin S, Huang Y, Lin J, Chou T, Hsueh C, Wong R . Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS One. 2012; 7(10):e46726. PMC: 3471922. DOI: 10.1371/journal.pone.0046726. View

20.

Tuttle R, Ball D, Byrd D, Dilawari R, Doherty G, Duh Q . Thyroid carcinoma. J Natl Compr Canc Netw. 2010; 8(11):1228-74. DOI: 10.6004/jnccn.2010.0093. View